Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial
Diffuse cutaneous systemic sclerosis (dcSSc) is one…
rheumnow.com
Comparison of immunosuppressants for early diffuse systemic sclerosis yields mixed results
Placing patients who have early diffuse cutaneous systemic sclerosis (dcSSc ) on an immunosuppressant regimen can have a beneficial, but not necessarily sustainable, impact, according to findings from the European Scleroderma Observational Study.
globalacademycme.com
Lymphotoxin B and Adipose Derived Stromal Cells Regulate Skin Fibrosis in Scleroderma
rheumnow.com
Potential Scleroderma Therapy Seen to Stop Inflammation in Phase 1 Trial
Read about a potential scleroderma treatment, Resunab by Corbus, that in a Phase 1 study showed efficacy in ending inflammation and was seen to be safe.
sclerodermanews.com
Targeted Therapy for Scleroderma Fibrosis
Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a…
the-rheumatologist.org
Intravenous Epoprostenol Warranted for Scleroderma Spectrum Digital Vasculopathy
By Brian Hoyle…
dgnews.docguide.com